ZEVRA THERAPEUTICS INC (ZVRA) Fundamental Analysis & Valuation

NASDAQ:ZVRA • US4884452065

Current stock price

9.4 USD
+0.27 (+2.96%)
At close:
9.25 USD
-0.15 (-1.6%)
Pre-Market:

This ZVRA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

3

1. ZVRA Profitability Analysis

1.1 Basic Checks

  • In the past year ZVRA was profitable.
  • In the past year ZVRA has reported a negative cash flow from operations.
  • In the past 5 years ZVRA reported 4 times negative net income.
  • In the past 5 years ZVRA reported 4 times negative operating cash flow.
ZVRA Yearly Net Income VS EBIT VS OCF VS FCFZVRA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50M -50M -100M

1.2 Ratios

  • ZVRA's Return On Assets of 26.73% is amongst the best of the industry. ZVRA outperforms 99.48% of its industry peers.
  • ZVRA has a better Return On Equity (49.20%) than 97.93% of its industry peers.
Industry RankSector Rank
ROA 26.73%
ROE 49.2%
ROIC N/A
ROA(3y)-19.57%
ROA(5y)-28.4%
ROE(3y)-96.76%
ROE(5y)-77.63%
ROIC(3y)N/A
ROIC(5y)N/A
ZVRA Yearly ROA, ROE, ROICZVRA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -100 -200 -300

1.3 Margins

  • With an excellent Profit Margin value of 71.47%, ZVRA belongs to the best of the industry, outperforming 98.45% of the companies in the same industry.
  • ZVRA has a Gross Margin of 96.37%. This is amongst the best in the industry. ZVRA outperforms 96.37% of its industry peers.
Industry RankSector Rank
OM N/A
PM (TTM) 71.47%
GM 96.37%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ZVRA Yearly Profit, Operating, Gross MarginsZVRA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -100 -200 -300 -400

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. ZVRA Health Analysis

2.1 Basic Checks

  • ZVRA does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for ZVRA has been increased compared to 1 year ago.
  • Compared to 5 years ago, ZVRA has more shares outstanding
  • ZVRA has a better debt/assets ratio than last year.
ZVRA Yearly Shares OutstandingZVRA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M 50M
ZVRA Yearly Total Debt VS Total AssetsZVRA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M 250M

2.2 Solvency

  • ZVRA has an Altman-Z score of 1.57. This is a bad value and indicates that ZVRA is not financially healthy and even has some risk of bankruptcy.
  • ZVRA has a Altman-Z score of 1.57. This is comparable to the rest of the industry: ZVRA outperforms 59.59% of its industry peers.
  • ZVRA has a Debt/Equity ratio of 0.40. This is a healthy value indicating a solid balance between debt and equity.
  • ZVRA has a Debt to Equity ratio of 0.40. This is comparable to the rest of the industry: ZVRA outperforms 40.41% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.4
Debt/FCF N/A
Altman-Z 1.57
ROIC/WACCN/A
WACC9.6%
ZVRA Yearly LT Debt VS Equity VS FCFZVRA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50M -50M 100M 150M

2.3 Liquidity

  • ZVRA has a Current Ratio of 5.68. This indicates that ZVRA is financially healthy and has no problem in meeting its short term obligations.
  • The Current ratio of ZVRA (5.68) is better than 67.88% of its industry peers.
  • A Quick Ratio of 5.63 indicates that ZVRA has no problem at all paying its short term obligations.
  • With a decent Quick ratio value of 5.63, ZVRA is doing good in the industry, outperforming 68.91% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 5.68
Quick Ratio 5.63
ZVRA Yearly Current Assets VS Current LiabilitesZVRA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

8

3. ZVRA Growth Analysis

3.1 Past

  • ZVRA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 159.73%, which is quite impressive.
  • The Revenue has grown by 350.91% in the past year. This is a very strong growth!
  • ZVRA shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 51.61% yearly.
EPS 1Y (TTM)159.73%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%130.43%
Revenue 1Y (TTM)350.91%
Revenue growth 3Y116.72%
Revenue growth 5Y51.61%
Sales Q2Q%183.36%

3.2 Future

  • ZVRA is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 22.31% yearly.
  • ZVRA is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 31.44% yearly.
EPS Next Y-58.07%
EPS Next 2Y10.15%
EPS Next 3Y25.8%
EPS Next 5Y22.31%
Revenue Next Year42.74%
Revenue Next 2Y47.98%
Revenue Next 3Y45.15%
Revenue Next 5Y31.44%

3.3 Evolution

  • Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
ZVRA Yearly Revenue VS EstimatesZVRA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 100M 200M 300M 400M
ZVRA Yearly EPS VS EstimatesZVRA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 -20 -40 -60 -80 -100

More info and screens

Find the best growth stocksShow best growing peers

5

4. ZVRA Valuation Analysis

4.1 Price/Earnings Ratio

  • A Price/Earnings ratio of 6.96 indicates a rather cheap valuation of ZVRA.
  • ZVRA's Price/Earnings ratio is rather cheap when compared to the industry. ZVRA is cheaper than 94.30% of the companies in the same industry.
  • When comparing the Price/Earnings ratio of ZVRA to the average of the S&P500 Index (25.23), we can say ZVRA is valued rather cheaply.
  • With a Price/Forward Earnings ratio of 16.60, ZVRA is valued correctly.
  • ZVRA's Price/Forward Earnings ratio is rather cheap when compared to the industry. ZVRA is cheaper than 81.35% of the companies in the same industry.
  • ZVRA's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 22.51.
Industry RankSector Rank
PE 6.96
Fwd PE 16.6
ZVRA Price Earnings VS Forward Price EarningsZVRA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ZVRA Per share dataZVRA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 1 1.5 2 2.5

4.3 Compensation for Growth

  • A more expensive valuation may be justified as ZVRA's earnings are expected to grow with 25.80% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y10.15%
EPS Next 3Y25.8%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. ZVRA Dividend Analysis

5.1 Amount

  • No dividends for ZVRA!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ZVRA Fundamentals: All Metrics, Ratios and Statistics

ZEVRA THERAPEUTICS INC

NASDAQ:ZVRA (3/26/2026, 8:00:02 PM)

Premarket: 9.25 -0.15 (-1.6%)

9.4

+0.27 (+2.96%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)03-09
Earnings (Next)05-11
Inst Owners68.35%
Inst Owner ChangeN/A
Ins Owners1.06%
Ins Owner Change31.38%
Market Cap551.87M
Revenue(TTM)106.47M
Net Income(TTM)76.10M
Analysts84.29
Price Target23.31 (147.98%)
Short Float %9.76%
Short Ratio4.71
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)191.88%
Min EPS beat(2)71.99%
Max EPS beat(2)311.77%
EPS beat(4)3
Avg EPS beat(4)107.86%
Min EPS beat(4)-20.8%
Max EPS beat(4)311.77%
EPS beat(8)4
Avg EPS beat(8)39.13%
EPS beat(12)5
Avg EPS beat(12)20.74%
EPS beat(16)6
Avg EPS beat(16)7.14%
Revenue beat(2)1
Avg Revenue beat(2)7.61%
Min Revenue beat(2)-4.04%
Max Revenue beat(2)19.27%
Revenue beat(4)3
Avg Revenue beat(4)11.44%
Min Revenue beat(4)-4.04%
Max Revenue beat(4)19.27%
Revenue beat(8)5
Avg Revenue beat(8)5.23%
Revenue beat(12)8
Avg Revenue beat(12)18.02%
Revenue beat(16)9
Avg Revenue beat(16)10.82%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)-29.44%
EPS NQ rev (3m)-29.44%
EPS NY rev (1m)0%
EPS NY rev (3m)-0.45%
Revenue NQ rev (1m)-1.68%
Revenue NQ rev (3m)-1.68%
Revenue NY rev (1m)-1.01%
Revenue NY rev (3m)-0.58%
Valuation
Industry RankSector Rank
PE 6.96
Fwd PE 16.6
P/S 5.18
P/FCF N/A
P/OCF N/A
P/B 3.57
P/tB 3.84
EV/EBITDA N/A
EPS(TTM)1.35
EY14.36%
EPS(NY)0.57
Fwd EY6.02%
FCF(TTM)-0.04
FCFYN/A
OCF(TTM)-0.03
OCFYN/A
SpS1.81
BVpS2.63
TBVpS2.44
PEG (NY)N/A
PEG (5Y)N/A
Graham Number8.95
Profitability
Industry RankSector Rank
ROA 26.73%
ROE 49.2%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) 71.47%
GM 96.37%
FCFM N/A
ROA(3y)-19.57%
ROA(5y)-28.4%
ROE(3y)-96.76%
ROE(5y)-77.63%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.37
Health
Industry RankSector Rank
Debt/Equity 0.4
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 20.6%
Cap/Sales 0.78%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.68
Quick Ratio 5.63
Altman-Z 1.57
F-Score6
WACC9.6%
ROIC/WACCN/A
Cap/Depr(3y)47.98%
Cap/Depr(5y)38.39%
Cap/Sales(3y)9.09%
Cap/Sales(5y)5.7%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)159.73%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%130.43%
EPS Next Y-58.07%
EPS Next 2Y10.15%
EPS Next 3Y25.8%
EPS Next 5Y22.31%
Revenue 1Y (TTM)350.91%
Revenue growth 3Y116.72%
Revenue growth 5Y51.61%
Sales Q2Q%183.36%
Revenue Next Year42.74%
Revenue Next 2Y47.98%
Revenue Next 3Y45.15%
Revenue Next 5Y31.44%
EBIT growth 1Y95.13%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year151.17%
EBIT Next 3Y55.77%
EBIT Next 5Y38.78%
FCF growth 1Y96.78%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y97.71%
OCF growth 3YN/A
OCF growth 5YN/A

ZEVRA THERAPEUTICS INC / ZVRA Fundamental Analysis FAQ

What is the fundamental rating for ZVRA stock?

ChartMill assigns a fundamental rating of 4 / 10 to ZVRA.


What is the valuation status for ZVRA stock?

ChartMill assigns a valuation rating of 5 / 10 to ZEVRA THERAPEUTICS INC (ZVRA). This can be considered as Fairly Valued.


What is the profitability of ZVRA stock?

ZEVRA THERAPEUTICS INC (ZVRA) has a profitability rating of 3 / 10.


What is the earnings growth outlook for ZEVRA THERAPEUTICS INC?

The Earnings per Share (EPS) of ZEVRA THERAPEUTICS INC (ZVRA) is expected to decline by -58.07% in the next year.